The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics. But how best to spend the HIV prevention budget so that the country can drive infections down as fast as possible? We take a look at what the modelling data shows
After a year of US funding cuts across global public health, including South Africa’s hard-hit HIV programmes, new realities are settling in
Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?
The country’s medicines regulator Sahpra says it’s on track to announce its registration decision by the end of October
Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot around R692 per person a year
The health department hopes to make the twice-a-year anti-HIV injection lenacapavir available soon and to be buying generics by 2027
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it has already been awarded and was cut by 16% in June